The kinetics of circulating lymphoid cells were evaluated in three children suffering from ␤-thalassemia major after HLA-identical sibling placental blood transplant (PBT) in one patient and placental blood plus bone marrow transplantation (BMT) in two patients. Recovery of the main lymphocyte subsets, as determined by phenotype analysis of circulating PBMCs, was complete within 2 months after transplant. NK (CD56 + ) cells were the first to appear in peripheral blood, followed by T (CD3 + , CD2 + , CD7 
In the last decade, the use of placental blood as a source of hematopoietic stem cells for transplantation has increased greatly. 1 Recent data have indicated that an adequate dose (3.7 × 10 7 ) of placental blood nucleated cells per kg of recipient's body weight is necessary to achieve stem-cell engraftment. 2 This technique seems to reduce the risk of either acute or chronic graft-versus-host disease (GVHD); [3] [4] [5] furthermore, placental blood transplantation (PMT) permits a greater degree of tolerance by the recipient of histoincompatible placental blood and thus makes the task of finding appropriate hematopoietic stem cells easier. Immune reconstitution has been well described in adults after unrelated or partially matched T cell-depleted bone marrow transplantation (BMT) or placental blood (PBT) or autologous transplantation, while only a few reports have been published concerning the pediatric population. [6] [7] [8] [9] [10] [11] [12] [13] Here, we report on the kinetics of lymphocyte reconstitution, as determined by phenotype analysis of circulating lymphocyte subsets, in three pediatric patients with ␤-thalassemia major treated with placental blood transplantation from HLA-identical siblings, heterozygous for ␤-thalassemia as diagnosed prenatally. Placental blood transplantation was supplemented by bone marrow grafts from the same donors in two patients since the number of nucleated cells in the placental blood was insufficient for stem cell engraftment.
Patients and methods
In patients with ␤-thalassemia major, HLA-haploidentical placental blood transplantation is performed as part of a cooperative program between the Department of Pediatrics and Division of Neonatal Intensive Care, University of Pavia and the Service for Prenatal Diagnosis of ␤-thalassemia, Chair of Hematology, University of Bari. In families with a child affected with ␤-thalassemia major, when the mother was pregnant again with a fetus at risk for ␤-thalassemia major, prenatal genetic analysis on biopsies of the placental villus was routinely performed at 11 weeks of gestation. HLA-typing was also performed on the same villus samples. If the fetus was not affected by, or was heterozygous for ␤-thalassemia, placental blood was harvested at birth, placed in sterile bags containing citrate phosphate dextrose (CPD) as anticoagulant, frozen as whole blood under controlled conditions and stored in the cord bank.
Placental blood transplantation (PBT)
Pre-transplant conditioning of patients was carried out with busulfan (4 mg/kg on day −10 and 5 mg/kg from day −9 to day −6), thiotepa (4 mg/kg twice daily on day −5) and cyclophosphamide (50 mg/kg from day −4 to day −1). Patients then received placental blood from their siblings. Since the number of nucleated cells in the stored placental blood was insufficient for stem cell engraftment in two patients, bone marrow stem cells harvested from the same sibling were also transplanted, after the parent's informed consent. To prevent graft-versus-host disease (GVHD), cyclosporin A was administered intravenously at a dose of 3-4 mg/kg 24 days after transplant and subsequently at a dose of 10 mg/kg twice daily. Granulocyte growth factor (G-CSF) was administered at a dose of 150 mg from day +4 to +15 as supportive therapy. Table 1 summarizes the main clinical characteristics of the transplanted patients.
Patient 1
The first recipient of PBT was a 5-year-old male with ␤-thalassemia major who required blood transfusions from the age of 18 months. After conditioning, he received 80 ml of placental blood from his male sibling heterozygous for ␤-thalassemia (genotype IVS 1 nt 110). A total of 8 × 10 /l and 26.0 × 10 9 /l, respectively; eight months after transplantation, he developed a herpes zoster viral infection. He had received cyclosporin A at a dose of 50-100 mg/day orally for 2 years. The molecular typing for the ␤-globin gene confirmed the genotype IVS 1 nt 110/N. The actual levels of hemoglobin, WBC and platelets are 11.5 g/dl, 7.5 × 10 9 /l and 239 × 10 9 /l, respectively.
Patient 2
The second patient was a 7-year-old male with ␤-thalassemia major and blood transfusion-dependent from the age of 18 months. After pre-transplant conditioning, the patient Table 1 Clinical parameters of three ␤-thalassemia major transplanted patients 
Patient 3
The third transplant recipient was a 3-year-old female with ␤-thalassemia major who required blood transfusion from the age of 7 months. After pre-transplant conditioning, she received 60 ml of placental blood from her female sibling, heterozygous for ␤-thalassemia genotype-87. Placental blood nucleated cells (2.6 × 10 7 /kg of recipient's body weight) were supplemented with bone marrow stem cells (1.2 × 10 7 /kg of body weight) obtained from the same sibling at the age of 6 months. Stem cell engraftment was documented 11 days after transplantation; WBC count was 1.2 × 10 9 cells/l with 0.8 × 10 9 neutrophils/l. Three units of red blood cells and two units of concentrated platelets were also provided. The patient had been treated with cyclosporin A 50-100 mg/day orally for 1 year. At discharge, her hemoglobin was 9.8 g/dl and the WBC and plt counts were 3.57 × 10 
Surface marker analysis of peripheral blood mononuclear cells (PBMC)
Peripheral blood samples were drawn from transplanted patients by venipuncture at sequential time points after transplant (every 50 days up to 800 days for patient 1, 500 days for patient 2, and 650 days for patient 3). Evaluation of the distribution of different circulating lymphocyte subsets was performed on whole blood aliquots by direct immunofluorescent staining with fluorochrome-conjugated monoclonal antibodies specific for leukocyte surface markers, and multiparameter analysis by flow cytometry with a FACScan cytometer (Becton Dickinson, Mountain View, 
Results
Two months after transplantation, circulating lymphocytes were more than 1.0 × 10 9 /l in all three patients. As shown in Table 2 , approximately 65% of these cells were positive for CD2, CD7 and CD3; 25% of cells were B cell-positive for CD19, and the residual cells stained for CD56, a marker of NK cells.
14 Figure 1 illustrates the kinetics of CD3 + and CD19 + lymphocyte reconstitution in the three patients. No significant differences were observed in the three patients studied.
In the first 100 days after transplantation, the ratios between the CD4 and CD8 T lymphocyte subsets were lower than 1; this finding is due to a more prompt recovery 
of CD8
+ lymphocytes (Figure 2) . A similar pattern of T cell subset reconstitution has also been reported in BMT recipients. [6] [7] [8] In our patients, CD4 + cells equaled or outnumbered the CD8 + lymphocytes within 200-250 days of transplantation; however, a slight and transient decrease in the CD4 + /CD8 + ratio was observed between 300 and 400 days after transplantation in the patient who underwent PBT only. The number of circulating cells expressing the NK-related molecules (CD56 and CD57) and the CD56 + /CD57 + ratio are shown in Figure 3 . In the PBT-only patient, CD56
+ cells outnumbered the CD57 + cells in the first 280 days after transplant whereas in patients 2 and 3, the CD56 + /CD57 + ratio behaved differently; in patient 2 the ratio was constantly near 1, while in patient 3 the ratio was permanently higher than 2 ( Figure 3) .
The analysis of the CD45 RA and RO isoform expression by T cells (Figure 4 ) demonstrates a prevalence of CD45RO cells in the first 100 days post-transplant in the patient who received PBT only; at the same time points, CD45RA + T lymphocytes outnumbered the CD45RO + cells by a 2:1 or 3:1 ratio in all three patients. 
/CD8
+ ratio after PBT (patient 1) and PBT + BMT (patients 2 and 3). 
/CD57
+ ratio after PBT (patient 1) and PBT + BMT (patients 2 and 3).
Discussion
Reconstitution of the immune system depends upon three main factors: the number of transplanted stem cells, the development of GVHD and immune-suppressive treatment. If an effective number of stem cells is transplanted and GVHD does not develop, and higher dose treatment with immune-suppressive drugs such as cyclosporin A is not required, prompt recovery of the immune system and its functions might be expected.
It has been reported that hematological reconstitution occurs later in recipients of stem cells from PB when compared to those from BMT. 15 The delayed recovery most likely depends on the reduced number of hematopoietic progenitor cells infused with PBT. In our patients receiving HLA-identical PBT alone or PB plus BM stem cells from their siblings, complete lymphocyte reconstitution was reached within 2 months after transplant suggesting that reconstitution of the lymphocyte subsets was not altered by significant infection and/or GVHD, with the exception of the first patient who developed a herpes zoster infection 8 months post-transplantation. This viral infection was most likely influenced by the low CD4
+ /CD8 + ratio and the expression of the CD57 molecule by NK and T lymphocytes.
The expression of CD57 by lymphoid cells increased progressively in patients 1 and 2, indicating that this surface molecule was expressed by cells other than CD56 + NK cells. Normal fetus and neonate lymphoid cells do not express the CD57 molecule which begins to progressively increase in children 2-4 years after birth. 16 The progressive glycosylation of proteins and lipids on the surface membrane of T and non-T NK cells determining the expression of CD57 haplotypes is probably related to multiple or chronic stimulation of the immune system by several antigens, mainly viral. 17, 18 Although significant numbers of B lymphocytes were observed in our patients shortly after transplantation, recovery of B lymphocytes was greatly delayed in recipients of BMT. 8 The early recovery of B cells in patients receiving PB stem cells might be related to the relatively high number of immature B cells in neonatal blood. [19] [20] [21] These transplanted cells probably follow the developmental process of B cell ontogeny which occurs in the normal neonate after birth. In fact, while memory B cells can be transplanted with adult bone marrow, 21 placental blood contains only immature B cells. 19, 20, 22, 23 The expression of the RA and RO isoforms of the CD45 leukocyte antigen 24 by circulating lymphocytes also seems to follow normal lymphoid ontogeny. The transient prevalence of lymphocytes expressing CD45RO in the PBT only patient, might reflect the proliferation of immature lymphocytes transplanted with the placental blood. Indeed, normal neonatal T lymphocytes positive for CD45RA rapidly convert to CD45RO expression after activation. 25 In conclusion, our preliminary data suggest that transplantation of HLA-identical stem cells from PB, or PB plus 747 BM cells from the same donor, permits a successful hematological engraftment and adequate recovery of lymphocytes in patients with ␤-thalassemia major. The three main lymphocyte subsets recover rapidly after transplantation as demonstrated by phenotype analysis of circulating lymphocytes. In the patients studied, a sizable number of B cells and a normal CD4 + /CD8 + ratio were reached at 60 and 240 days, respectively. The phenotypic and functional peculiarities of stem cells and immature lymphocytes in umbilical cord blood and the age of BM donors might account for the rapid increase in the number of B cells, the absence of infections and the lack of severe manifestations of acute or chronic GVHD.
